Effect of zoledronic acid on bone healing subsequent to mini-implant insertion.
OBJECTIVE
To examine remodeling in bone supporting mini-implants by comparing a no drug (ND) group with a group that received a potent intravenous bisphosphonate in a canine model.


METHODS
Twelve skeletally mature (2- to 3-year-old) male dogs were divided into two groups. Seven dogs were administered 0.1 mg/kg/mo of zoledronic acid (ZA) for 16 weeks, while five age-matched dogs received no drug. Two mini-implants (Tomas, Dentaurum, Newton, Pa) were placed unilaterally in the maxilla and mandible (4 mini-implants per animal × 12  =  48). Serial fluorescent bone labels were administered in vivo. Postmortem, the bone blocks containing the mini-implants were harvested and used for histomorphometric analyses at two regions of interest (adjacent: within 1 mm of interface; distant: 1-4 mm from the interface) supporting the mini-implant. Data were analyzed using mixed models.


RESULTS
In general, the ZA group had a significantly lower bone formation rate than the ND group (P < .05) for all jaws/regions except for the adjacent region in the maxilla, P  =  .12. Despite the reduction, mean intracortical remodeling in the ZA group ranged from 35%-42% per year in the implant adjacent bone. This rate is substantially higher than that reported for noninjured sites in the jaw.


CONCLUSIONS
Bone remodeling is typically elevated in implant supporting bone. After ZA administration, the healing response represented by elevated turnover in implant supporting bone was diminished but was not abolished.
Division of Orthodontics, College of Dentistry, The Ohio State University, Columbus, Ohio 43210, USA.
Sarandeep S
SS
Huja
Burçak
B
Kaya
X
X
Mo
Andrew M
AM
D'Atri
Soledad A
SA
Fernandez
D000539:Alveolar Process / Q000187:drug effects; D000818:Animals; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000494:pharmacology*; D016723:Bone Remodeling / Q000187:drug effects*; D003758:Dental Implantation, Endosseous; D004164:Diphosphonates / Q000008:administration & dosage / Q000494:pharmacology*; D004285:Dogs; D007093:Imidazoles / Q000008:administration & dosage / Q000494:pharmacology*; D007275:Injections, Intravenous; D008297:Male; D008904:Miniaturization; D014945:Wound Healing / Q000187:drug effects; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid
J Oral Implantol. 2006;32(3):110-6
16836174
J Vet Intern Med. 2008 Mar-Apr;22(2):380-7
18346146
J Clin Oncol. 2009 Nov 10;27(32):5356-62
19805682
Bone. 1999 Aug;25(2):217-22
10456388
J Oral Implantol. 1986;12(3):406-16
3470526
Anat Rec A Discov Mol Cell Evol Biol. 2006 Dec;288(12):1243-9
17075846
Am J Orthod Dentofacial Orthop. 2007 Mar;131(3):311-20
17346585
Calcif Tissue Res. 1969;3(3):211-37
4894738
Calcif Tissue Int. 2006 Oct;79(4):255-61
17033724
Implant Dent. 1995 Winter;4(4):235-43
8603133
J Dent Res. 1979 Oct;58(10):1953-69
291620
Acta Anat (Basel). 1970;76(1):1-15
4099686
Bone. 1989;10(4):255-64
2803861
J Oral Maxillofac Surg. 2008 May;66(5):987-94
18423290
J Dent Res. 2003 May;82(5):377-81
12709505
Am J Orthod. 1984 Aug;86(2):95-111
6589962
Int J Oral Maxillofac Implants. 1995 Jan-Feb;10(1):74-8
7615320
J Bone Miner Res. 1987 Dec;2(6):595-610
3455637
Clin Oral Implants Res. 2009 Sep;20 Suppl 4:87-95
19663954
Am J Orthod Dentofacial Orthop. 2006 Jul;130(1):18-25
16849067
Henry Ford Hosp Med J. 1983;31(1):3-9
6345475
Prog Orthod. 2007;8(1):192-201
17580417
J Bone Miner Res. 2010 Jan;25(1):98-105
19580463
J Dent Res. 2007 Nov;86(11):1022-33
17959891
J Clin Oncol. 2005 Dec 1;23(34):8580-7
16314620
Lancet Oncol. 2006 Jun;7(6):508-14
16750501